The role of TRAF3 mutations in MM has not been fully elucidated; while several publications indicate that they are a marker of aggressive disease and resistance to proteasome inhibitors [31], data from both the CoMMpass cohort and ours suggest that combined therapy, including proteasome inhibitors may ameliorate outcomes in these patients, in line with some preclinical studies [32]. The gene discussed is TRAF3; the disease is Miyoshi myopathy.